Drug Shortage Report for MITOXANTRONE INJECTION
| Report ID | 112481 |
| Drug Identification Number | 02286300 |
| Brand name | MITOXANTRONE INJECTION |
| Common or Proper name | MitoXANTRONE Injection |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MITOXANTRONE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 2 mg/mL SD Vial 10 mL |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-04-17 |
| Estimated end date | 2020-04-30 |
| Actual end date | 2020-04-30 |
| Shortage status | Resolved |
| Updated date | 2020-05-06 |
| Company comments | Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our MitoXANTRONE Injection, 2 mg/mL, SD Vial, 10 mL will be available at all distribution centres today, Thursday, April 30th, 2020 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2020-05-06 | French | Compare |
| v3 | 2020-05-06 | English | Compare |
| v2 | 2020-04-20 | French | Compare |
| v1 | 2020-04-20 | English | Compare |
Showing 1 to 4 of 4